{"id":58667,"date":"2026-03-03T16:17:58","date_gmt":"2026-03-03T08:17:58","guid":{"rendered":"https:\/\/flcube.com\/?p=58667"},"modified":"2026-03-03T16:17:58","modified_gmt":"2026-03-03T08:17:58","slug":"huadong-medicines-dr30206-wins-nmpa-approval-triple-target-fusion-protein-for-nsclc-enters-phase-ii","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58667","title":{"rendered":"Huadong Medicine&#8217;s DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE:\u202f000963<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved a <strong>clinical study<\/strong> for <strong>DR30206<\/strong>, a <strong>Category\u202f1 therapeutic biologic<\/strong>, in <strong>combination with standard therapy<\/strong> for <strong>locally advanced or metastatic non\u2011small cell lung cancer (NSCLC)<\/strong>. The <strong>triple\u2011target fusion protein<\/strong>\u2014targeting <strong>PD\u2011L1, VEGF, and TGF\u2011\u03b2<\/strong>\u2014advances into <strong>Phase II development<\/strong> following its <strong>initial IND clearance for advanced solid tumors in June\u202f2023<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Huadong Medicine Co., Ltd (SHE:\u202f000963)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>DR30206<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category\u202f1 therapeutic biologic; fusion protein<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td><strong>PD\u2011L1 + VEGF + TGF\u2011\u03b2<\/strong> (triple\u2011target)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA clinical study approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced or metastatic NSCLC (combination with standard therapy)<\/td><\/tr><tr><td><strong>Prior Approval<\/strong><\/td><td>June\u202f2023: IND for advanced solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-triple-target-immunotherapy\">Mechanism of Action \u2013 Triple\u2011Target Immunotherapy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target<\/th><th>Mechanism<\/th><th>Therapeutic Effect<\/th><\/tr><\/thead><tbody><tr><td><strong>PD\u2011L1<\/strong><\/td><td>Blocks PD\u20111\/PD\u2011L1 signaling<\/td><td>Restores exhausted CD8+ T\u2011cell proliferation; reactivates anti\u2011tumor immunity<\/td><\/tr><tr><td><strong>VEGF<\/strong><\/td><td>Binds free VEGF<\/td><td>Reduces tumor angiogenesis; normalizes vasculature for improved drug delivery<\/td><\/tr><tr><td><strong>TGF\u2011\u03b2<\/strong><\/td><td>Binds free TGF\u2011\u03b2<\/td><td>Reverses immunosuppression; enhances T\u2011cell infiltration and function<\/td><\/tr><tr><td><strong>Combined Effect<\/strong><\/td><td>Triple pathway blockade<\/td><td><strong>Synergistic anti\u2011tumor immunity + anti\u2011angiogenesis + microenvironment modulation<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Triple\u2011Target Differentiation:<\/strong> DR30206&#8217;s <strong>simultaneous PD\u2011L1\/VEGF\/TGF\u2011\u03b2 blockade<\/strong> represents a <strong>next\u2011generation immuno\u2011oncology approach<\/strong>, potentially <strong>superior to dual\u2011target bispecifics<\/strong> (e.g., PD\u20111\/VEGF) by <strong>addressing TGF\u2011\u03b2\u2011mediated immunosuppression<\/strong>\u2014a key resistance mechanism in NSCLC.<\/li>\n\n\n\n<li><strong>NSCLC Market Positioning:<\/strong> Targeting <strong>locally advanced\/metastatic NSCLC<\/strong>\u2014the <strong>largest cancer indication globally<\/strong>\u2014with <strong>standard therapy combination<\/strong> positions DR30206 for <strong>front\u2011line or second\u2011line use<\/strong>, competing with <strong>pembrolizumab, atezolizumab, and emerging bispecifics<\/strong>.<\/li>\n\n\n\n<li><strong>Fusion Protein Advantage:<\/strong> <strong>Single\u2011molecule triple targeting<\/strong> ensures <strong>coordinated pharmacokinetics<\/strong> and <strong>simplified manufacturing<\/strong> vs. combination regimens requiring multiple agents, potentially improving <strong>patient compliance<\/strong> and <strong>cost\u2011effectiveness<\/strong>.<\/li>\n\n\n\n<li><strong>Huadong Innovation Pipeline:<\/strong> <strong>Category\u202f1 biologic status<\/strong> demonstrates Huadong&#8217;s <strong>transition from traditional pharma (generics, APIs) to innovative biologics<\/strong>, supporting <strong>valuation re\u2011rating<\/strong> and <strong>partnership attractiveness<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>NSCLC Market Size<\/strong><\/td><td>~\u202f$25\u202fbillion globally; immunotherapy dominates first\u2011line; resistance mechanisms drive demand for next\u2011gen combinations<\/td><\/tr><tr><td><strong>TGF\u2011\u03b2 Inhibition Trend<\/strong><\/td><td>TGF\u2011\u03b2 blockade (e.g., bintrafusp alfa) previously failed; DR30206&#8217;s <strong>triple\u2011target approach<\/strong> may overcome single\u2011agent TGF\u2011\u03b2 limitations<\/td><\/tr><tr><td><strong>PD\u20111\/VEGF Bispecific Competition<\/strong><\/td><td>Ivonescimab (Akeso), AK112 (Akeso) gaining traction; DR30206&#8217;s <strong>TGF\u2011\u03b2 addition<\/strong> may differentiate in TGF\u2011\u03b2\u2011high tumor microenvironments<\/td><\/tr><tr><td><strong>China Biologics Innovation<\/strong><\/td><td>NMPA&#8217;s rapid approval of complex fusion proteins signals regulatory maturity; Huadong joins leading domestic immuno\u2011oncology developers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase II enrollment, combination safety profile, and efficacy outcomes for DR30206 in NSCLC. Actual results may differ due to risks including triple\u2011target toxicity, competitive bispecific launches, and manufacturing complexity for fusion proteins.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-ff38fd8d-bbb4-4a9f-b9ed-5338ae794a28\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ff38fd8d-bbb4-4a9f-b9ed-5338ae794a28\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd (SHE:\u202f000963) announced that China&#8217;s National Medical Products Administration (NMPA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,114,18,887],"class_list":["post-58667","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-huadong-medicine","tag-pd-1-l1","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine&#039;s DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd (SHE:\u202f000963) announced that China&#039;s National Medical Products Administration (NMPA) has approved a clinical study for DR30206, a Category\u202f1 therapeutic biologic, in combination with standard therapy for locally advanced or metastatic non\u2011small cell lung cancer (NSCLC). The triple\u2011target fusion protein\u2014targeting PD\u2011L1, VEGF, and TGF\u2011\u03b2\u2014advances into Phase II development following its initial IND clearance for advanced solid tumors in June\u202f2023.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58667\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine&#039;s DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd (SHE:\u202f000963) announced that China&#039;s National Medical Products Administration (NMPA) has approved a clinical study for DR30206, a Category\u202f1 therapeutic biologic, in combination with standard therapy for locally advanced or metastatic non\u2011small cell lung cancer (NSCLC). The triple\u2011target fusion protein\u2014targeting PD\u2011L1, VEGF, and TGF\u2011\u03b2\u2014advances into Phase II development following its initial IND clearance for advanced solid tumors in June\u202f2023.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58667\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T08:17:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58667#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58667\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine&#8217;s DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II\",\"datePublished\":\"2026-03-03T08:17:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58667\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Huadong Medicine\",\"PD-1\\\/L1\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58667#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58667\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58667\",\"name\":\"Huadong Medicine's DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-03T08:17:58+00:00\",\"description\":\"Huadong Medicine Co., Ltd (SHE:\u202f000963) announced that China's National Medical Products Administration (NMPA) has approved a clinical study for DR30206, a Category\u202f1 therapeutic biologic, in combination with standard therapy for locally advanced or metastatic non\u2011small cell lung cancer (NSCLC). The triple\u2011target fusion protein\u2014targeting PD\u2011L1, VEGF, and TGF\u2011\u03b2\u2014advances into Phase II development following its initial IND clearance for advanced solid tumors in June\u202f2023.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58667#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58667\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58667#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine&#8217;s DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine's DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd (SHE:\u202f000963) announced that China's National Medical Products Administration (NMPA) has approved a clinical study for DR30206, a Category\u202f1 therapeutic biologic, in combination with standard therapy for locally advanced or metastatic non\u2011small cell lung cancer (NSCLC). The triple\u2011target fusion protein\u2014targeting PD\u2011L1, VEGF, and TGF\u2011\u03b2\u2014advances into Phase II development following its initial IND clearance for advanced solid tumors in June\u202f2023.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58667","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine's DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II","og_description":"Huadong Medicine Co., Ltd (SHE:\u202f000963) announced that China's National Medical Products Administration (NMPA) has approved a clinical study for DR30206, a Category\u202f1 therapeutic biologic, in combination with standard therapy for locally advanced or metastatic non\u2011small cell lung cancer (NSCLC). The triple\u2011target fusion protein\u2014targeting PD\u2011L1, VEGF, and TGF\u2011\u03b2\u2014advances into Phase II development following its initial IND clearance for advanced solid tumors in June\u202f2023.","og_url":"https:\/\/flcube.com\/?p=58667","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-03T08:17:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58667#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58667"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine&#8217;s DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II","datePublished":"2026-03-03T08:17:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58667"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Huadong Medicine","PD-1\/L1","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58667#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58667","url":"https:\/\/flcube.com\/?p=58667","name":"Huadong Medicine's DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-03T08:17:58+00:00","description":"Huadong Medicine Co., Ltd (SHE:\u202f000963) announced that China's National Medical Products Administration (NMPA) has approved a clinical study for DR30206, a Category\u202f1 therapeutic biologic, in combination with standard therapy for locally advanced or metastatic non\u2011small cell lung cancer (NSCLC). The triple\u2011target fusion protein\u2014targeting PD\u2011L1, VEGF, and TGF\u2011\u03b2\u2014advances into Phase II development following its initial IND clearance for advanced solid tumors in June\u202f2023.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58667#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58667"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58667#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine&#8217;s DR30206 Wins NMPA Approval \u2013 Triple\u2011Target Fusion Protein for NSCLC Enters Phase II"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58667"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58667\/revisions"}],"predecessor-version":[{"id":58678,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58667\/revisions\/58678"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}